| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $15,774,817 ) (Continued on the next page) |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P30CA076292 | Moffitt Cancer Center Support Grant | 003 | 26 | NIH | 3/8/2024 | -$145,467 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA288927 | Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers | 000 | 1 | NIH | 3/27/2024 | $236,321 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 1 | NIH | 12/19/2023 | $549,937 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA286417 | Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer | 000 | 1 | NIH | 1/12/2024 | $196,934 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA286682 | Targeting ULK3 for the treatment of triple negative breast cancer | 000 | 1 | NIH | 11/23/2023 | $84,250 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA286226 | L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity | 000 | 1 | NIH | 12/13/2023 | $236,321 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99GM154063 | Dual E3 ligase function of TRIM25 in modulating innate immunity | 000 | 1 | NIH | 4/19/2024 | $110,335 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA283730 | Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients | 000 | 1 | NIH | 4/15/2024 | $460,204 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA280404 | Investigating lipid phenotype as a metabolic adaptation to microenvironmental stress | 000 | 1 | NIH | 3/22/2024 | $84,250 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R33NS119658 | Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2 | 002 | 4 | NIH | 4/18/2024 | $29,690 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R33NS119658 | Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2 | 001 | 4 | NIH | 1/9/2024 | $381,715 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99CA271040 | Mindfulness-based ecological momentary intervention for smoking cessation among cancer survivors | 000 | 2 | NIH | 3/18/2024 | $118,825 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03DE030580 | Integrative analysis to identify genomic biomarkers in HPV positive oral cancer | 000 | 2 | NIH | 4/8/2024 | $151,650 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA280233 | KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function | 001 | 2 | NIH | 4/17/2024 | $11,817 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA280233 | KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function | 000 | 2 | NIH | 3/4/2024 | $212,689 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 001 | 2 | NIH | 4/17/2024 | $26,790 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 000 | 2 | NIH | 11/3/2023 | $482,202 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 001 | 2 | NIH | 4/17/2024 | $29,863 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 000 | 2 | NIH | 2/15/2024 | $537,519 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 001 | 2 | NIH | 4/17/2024 | $32,840 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 000 | 2 | NIH | 12/20/2023 | $591,131 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA267283 | Developing GRB2-PROTACs for Treatment of Lung Cancer | 001 | 2 | NIH | 4/17/2024 | $9,845 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA267283 | Developing GRB2-PROTACs for Treatment of Lung Cancer | 000 | 2 | NIH | 12/1/2023 | $177,242 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03AI175796 | The role of HPV E1 in regulating the NRF2-KEAP1 pathway | 000 | 2 | NIH | 11/20/2023 | $75,825 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA277288 | Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets | 001 | 2 | NIH | 4/17/2024 | $9,845 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA277288 | Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets | 000 | 2 | NIH | 12/20/2023 | $177,242 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R00CA241072 | Exploring the impact of HSP90 inhibition on antigen presentation and anti-tumor immune responses | 001 | 5 | NIH | 4/17/2024 | $24,900 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R00CA241072 | Exploring the impact of HSP90 inhibition on antigen presentation and anti-tumor immune responses | 000 | 5 | NIH | 2/8/2024 | $224,099 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K22CA262352 | Tele-resistance training during chemotherapy for advanced upper gastrointestinal cancer | 000 | 3 | NIH | 2/14/2024 | $161,973 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | D43CA260649 | Ghana IntegRative Approach to Cancer ResEarch Training: The Grace Program | 000 | 4 | NIH | 4/10/2024 | $273,570 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 000 | 4 | NIH | 2/27/2024 | $370,575 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM142577 | New reagents for C-C and C-N bond formation | 000 | 4 | NIH | 4/15/2024 | $370,575 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE030123 | Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | 000 | 5 | NIH | 4/2/2024 | $451,837 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 001 | 4 | NIH | 4/18/2024 | $23,802 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 000 | 4 | NIH | 3/11/2024 | $428,435 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA258089 | Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | 001 | 4 | NIH | 4/17/2024 | $32,002 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA258089 | Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | 000 | 4 | NIH | 3/6/2024 | $576,018 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255265 | Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | 000 | 4 | NIH | 3/19/2024 | $532,143 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255265 | Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | 001 | 4 | NIH | 4/16/2024 | $29,564 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 001 | 4 | NIH | 4/17/2024 | $22,230 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 4 | NIH | 2/9/2024 | $400,130 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01HL151579 | Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms | 000 | 4 | NIH | 1/15/2024 | $426,425 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA250276 | CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer | 000 | 5 | NIH | 4/10/2024 | $415,572 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249689 | CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health) | 001 | 5 | NIH | 4/18/2024 | $31,626 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249689 | CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health) | 000 | 5 | NIH | 2/19/2024 | $569,287 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA233601 | Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma | 001 | 5 | NIH | 4/17/2024 | $24,859 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA233601 | Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma | 000 | 5 | NIH | 1/30/2024 | $447,478 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241169 | Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on ?? T cells, in the bone microenvironment. | 001 | 5 | NIH | 4/16/2024 | $21,772 |
| | 2024 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA241169 | Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on ?? T cells, in the bone microenvironment. | 000 | 5 | NIH | 1/18/2024 | $391,943 |
|
